AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03768479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FES-PET
Description: 18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant
Study NCT03355417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OT-SI
Description: Occupational therapy using a sensory integration approach (OT-SI) 3x per week for 10 weeks. A typical session will be 1 hour (total of 3 hours per week).
Study NCT02822222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium citrate, tribasic anhydrous soft gelatin capsule
Description: 110 mg elemental magnesium/capsule
Study NCT02822222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft gelatin capsule
Description: 0 mg elemental magnesium/capsule
Study NCT06449040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B (AmBisome®)
Description: Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved
Study NCT00643916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular (at age 9 and 12 months)
Study NCT00643916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular (at age 9 and 15 months)
Study NCT00643916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular (at age 12 and 15 months)
Study NCT00643916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular (at age 15 months)
Study NCT00643916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular (at age 18 months)
Study NCT00643916 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
Description: 0.5 mL, Subcutaneous (at 3 years to \<6 years of age)
Study NCT05279781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical root canal treatment
Description: Complete root canal treatment will be performed followed by direct restoration
Study NCT05279781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Full pulpotomy followed by direct restoration
Study NCT02101229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, Asp(B28)-
Description: the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient
Study NCT01494337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HOLEP
Description: USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
Study NCT01494337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVEP-XPS
Description: Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
Study NCT01785680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Protocol
Description: Implement an integrated protocol in Sierra Leone for the management of MAM and non-complicated SAM that uses a single anthropometric indicator as well as the same food but in different doses to treat the continuum of malnutrition. MAM children will be given 75 g/kg/day of RUTF whereas SAM will be given 175 gr/kg/day of RUTF until MUAC>12.5 cm is reached. Then child will be given LNS, a bed net, albendazole, zinc, referral for immunizations compliant with current WHO recommendations, oral rehydration salts to give if the child has more than three loose watery stools in 24 hours, and asked to return for follow-up in 1, 3 and 6 months. Caretakers will be instructed to seek medical care sooner if the child has fever, poor appetite or signs of an acute illness.
Study NCT01785680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current protocol
Description: Current protocol for treating MAM in emergencies is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. This treatment is the standard today for treating children with MAM.
Study NCT01799564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micropulse
Description: Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
Study NCT04796441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-γδT
Description: Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
Study NCT01315093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, Low-Molecular-Weight
Description: Heparin from start till hcg test
Study NCT01315093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no heparin
Study NCT03982602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Subjects will be provided with the Ketogenic diet in the form of tube feeds once the decision is made to start the patient on diet.
Study NCT03544346 — intervention group
Intervention type: OTHER
Intervention: Exploratory brain and general health assessment
Description: Exploratory brain and general health assessment
Study NCT03393000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate plus SOC
Description: Trans Sodium Crocetinate (TSC) plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
Study NCT03393000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
Study NCT02686580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagen paste
Description: Permacol cross-linked collagen paste, 2.5-3.5 mls to be injected into the MRI defined fistula tracts 7-10 days following drainage of the anorectal abscess.
Study NCT02265302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 oral solution
Study NCT02265302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 wetability improved formulation (WIF) tablets
Study NCT02265302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01313702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polipillV1
Description: polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
Study NCT01313702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polipillV2
Description: Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
Study NCT01313702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: the drugs used in clinical practice, defined by physician
Study NCT02982694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.
Study NCT02982694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
Study NCT01519531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
Study NCT01519531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-3196
Description: Oral, daily dosing for 14 days
Study NCT00630110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel (75 mg/m2)
Study NCT00630110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-2358 + docetaxel
Description: NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
Study NCT00969384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active awareness/Lifestyle counseling
Description: Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided.
Study NCT03496506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)
Study NCT03496506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Each film-coated tablet containing 75 mg of clopidogrel (oral use)
Study NCT01278355 — intervention group
Intervention type: DEVICE
Intervention: Ear acupuncture
Description: Ear acupuncture
Study NCT01010594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary treatment
Description: A standard dietary treatment except that they are advised to restrict their fruit intake.
Study NCT01010594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary treatment
Description: A standard dietary treatment.
Study NCT02203474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 5 mcg
Study NCT02203474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg Capsule
Study NCT02203474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01642680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A tailored physical activity program during chemotherapy
Description: The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
Study NCT03192059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Efficacy of the combined treatment
Study NCT03192059 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Efficacy of the combined treatment
Study NCT03192059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Efficacy of the combined treatment
Study NCT03192059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Efficacy of the combined treatment
Study NCT03192059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Efficacy of the combined treatment
Study NCT03192059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Efficacy of the combined treatment
Study NCT03192059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Efficacy of the combined treatment
Study NCT01021995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: echinacea
Description: drops, 0.9 ml, tid for 4 months
Study NCT01021995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: drops, 0.9 ml tid for 4 months
Study NCT04134767 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Overdose Education
Description: Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.
Study NCT00089063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Description: Given SC
Study NCT01642680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A tailored physical activity program after chemotherapy
Description: The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
Study NCT00089063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC
Study NCT00089063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Given SC
Study NCT02565914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed dose tablet for oral administration.
Study NCT00089063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC
Study NCT00089063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC
Study NCT00089063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT00089063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01294696 — intervention group
Intervention type: DRUG
Intervention: Standard of care for treatment of osteoarthritis (OA) of knee(s)
Description: All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
Study NCT02565628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: 1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
Study NCT02676219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RS01
Description: Oral Care product containing sodium monofluorophosphate and sodium fluoride
Study NCT02676219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study NCT01492582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)
Description: Given IM
Study NCT01492582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01492582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study NCT01492582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Description: Ancillary studies
Study NCT03781856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: La Vida Buena Program
Description: The intervention is series of interactive one hour weekly classes over the course of 8 weeks related to child healthy weight, exercise and nutrition. Facilitated by community health workers, the classes are interactive and play-based and designed to engage both the child and accompanying parent or guardian in activities.
Study NCT03781856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Educational Session
Description: A one hour session about nutrition and physical activity to address obesity facilitated by a community health worker
Study NCT02716883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMT
Description: The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. The operated eye was patched for 2 h, and then administration of the medical treatment agents was resumed.~In patients in the case group AMT was performed during days 2-5 of antibiotic therapy when initial clinical response to the treatment was observed.
Study NCT00859625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nurse observation during colonoscope withdrawal
Description: nurse observation during colonoscope withdrawal
Study NCT02565628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02565914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT01460550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy
Description: The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.
Study NCT01460550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy
Description: The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
Study NCT00234052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
Study NCT00234052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
Study NCT00234052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
Study NCT02275455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real life situations
Description: Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
Study NCT02723864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib + VX-970 + Cisplatin
Description: Ataxia-telangiectasia-related (ATR) protein kinase is central to the deoxyribonucleic acid (DNA) damage response and homologous recombination, activating a series of phosphorylation cascades, culminating in cell cycle arrest to allow time for DNA repair. Poly (ADP-ribose) polymerase (PARP) plays a pivotal role in base-excision repair of single strand breaks formed either due to direct genotoxic stress or during the processing of double strand breaks. Preclinical studies show ATR inhibitor M6620 (VX-970) synergizes with cisplatin to induce DNA damage and antitumor activity. The addition of PARP inhibitor veliparib with VX-970 allows for impairment of DNA repair, induction of a breast cancer gene (BRCA) null phenotype, and potentiation of the antitumor activity of cisplatin.
Study NCT03148470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham iTBS
Description: Placebo stimulation for the iTBS group
Study NCT03148470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham cTBS
Description: Placebo stimulation for the cTBS group
Study NCT03148470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Description: Excitatory theta burst stimulation
Study NCT03148470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (cTBS)
Description: inhibitory theta burst stimulation
Study NCT03919136 — intervention group
Intervention type: DEVICE
Intervention: Wrist-worn measurement device (LiveMetric)
Description: Evaluation of the wrist-worn measurement devices accuracy referenced to interventional (A-line) measurements.
Study NCT02047045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
Study NCT02047045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 32 weeks.
Study NCT00526266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Description: A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
Study NCT00526266 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diaphragmatic Breathing (DB)
Description: Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping.